青霉烷砜／头孢哌酮治疗急性下呼吸道细菌性感染的对照性临床研究

COMPARATIVE CLINICAL STUDY OF THE TREATMENT OF ACUTE LOWER RESPIRATORY TRACT BACTERIAL INFECTION WITH SULBACTUM

青霉烷砜／头孢哌酮是β－内酰胺酶抑制剂（青霉烷砜）与头孢哌酮联合的新型头孢菌素，具有很广的抗菌谱与很高的抗菌活性，尤其是对产生β－内酰胺酶细菌的作用。本研究用青霉烷砜／头孢哌酮２．０ｇ，１２ｈ一次静点，与头孢噻肟２．０－４．０ｇ，８－１２ｈ一次静点，疗程７－１４ｄ治疗急性下呼吸道细菌感染５０对，取得了良好的临床及细菌学疗效。两药临床有效率分别为８８％，８６％，细菌清除率为８６％，８２％，不良反应发生率８％，１０％，主要为消化道症状及轻度转氨酶升高。

Sulbactum is a new type of cepholosporin combining the inhibitor of β-lactamase with cefoperazone. It has very wide antibacterial spectrum and very high antibacterial activity,especially on the bacteria raising up β-lactamase. In the study, we treated fifty pairs of incidences of acute lower respiratory tract bacterial infection for 7-14 days with sulperazon 2.0 g q 12 h intravenous and cefotaxime 2.0-4.0g q 8-12 h intravenous,and we got favorable clinical and bacteriological curative effects.The effective rates of the two kinds of drugs were 88%,86% respectively. Bacterial cleaning rates 86% and 82% and production rates of adverse reactions were 8% and 10% respectively.The main adverse reactions were gastruinterstinal symptoms and slight elevation of transamimase.